D
D-Sight
D-Sight is a clinical-stage biotech spin-off of the Vall d'Hebron Institute of Research (VHIR) developing first-in-class neuroprotective eye drops to halt vision loss in retinal neurodegenerative diseases, starting with early-stage diabetic retinopathy and expanding into glaucoma. Founded in 2023, it has raised roughly €5M in combined private and public funding (including a €1M round and a later €2M round led by Clave Capital, plus €1.5M from Spain's Public-Private Collaboration programme) and launched its first-in-human clinical trial, targeting a Series A to fund Phase II. It is headquartered in Barcelona and is a very small team (2-10 employees).
SectorsBiotech, Ophthalmology, Drug Development, Healthtech, Life Sciences
Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers
Founders
C
Carla Maté Goldar
CEO & Co-founder
C
Cristina Hernández Pascual
CSO & Co-founder
R
Rafael Simó Canonge
CMO & Co-founder
Global models 5
OOculis
Switzerland · oculis.com ↗
Clinical-stage biotech developing eye-drop treatments for retinal disease (diabetic macular oedema) and a neuroprotective drug for the optic nerve, planning to license or sell to pharma.
~$250MComparable
E
EyeBio
United Kingdom · eyebio.com ↗
VC-backed clinical-stage biotech developing a new drug for diabetic retinopathy and macular oedema; Merck bought it in 2024, which is the exit route D-Sight is aiming for.
~$130MComparable
OONL Therapeutics
United States · onltherapeutics.com ↗
Clinical-stage biotech developing first-in-class drugs that protect retinal cells and preserve vision in retinal diseases.
~$100MComparable
O
OcuTerra Therapeutics
United States · ocuterratx.com ↗
Clinical-stage biotech developing eye drops for early diabetic retinopathy, the same first target and delivery route as D-Sight.
~$50MComparable
PPerfuse Therapeutics
United States · perfusetherapeutics.com ↗
Clinical-stage biotech developing eye-drop drugs for glaucoma and diabetic retinopathy that aim to stop damage to the retina and optic nerve and halt vision loss.
~$40MComparable
In the same niche 67 others
See all in the Start-ups Map →
Notes: Most funded first
Investors 4
Open as list →
CClave Capital
clave.capital
I
Institut Català de Finances
icf.cat
B
BioAngels Club
P
Prous Institute for Biomedical Research
Funding rounds 2
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-02-23 | Seed | €2M |
Clave Capital
+3 more
|
| 2023-05-02 | Seed (estimated) | €1M | Clave Capital |
News 6
Open as list →| Published | Article |
|---|---|
| 2026-03-12 |
D-Sight Secures €2 Million to Advance Clinical Validation of Its Neuroprotective Therapies ↗
Catalonia.health
2026-03-12 |
| 2026-02-23 |
D-Sight, a Vall d'Hebron spin-off, launches its first-in-human clinical trial of neuroprotective therapies for diabetic retinopathy and glaucoma ↗
Biotech Spain
2026-02-23 |
| 2025-06-10 |
D-Sight: el principio del fin para los problemas de visión asociados a la diabetes ↗
Innovaspain
2025-06-10 |
| 2024-09-04 |
Carla Maté (D-Sight): «Estamos desarrollando el primer fármaco para tratar de forma precoz la retinopatía diabética, la principal causa de ceguera prevenible en edad laboral» ↗
Foment del Treball
2024-09-04 |
| 2024-05-13 |
D-Sight partners with Famar Group for CMC development and Clinical Batch Manufacturing ↗
D-Sight (press release)
2024-05-13 |
| 2023-11-21 |
The Vall d'Hebron spin-off D-Sight is awarded in the EIT Health InnoStars 2023 European competition ↗
Vall d'Hebron Research Institute (VHIR)
2023-11-21 |